Based in Ocala, Florida, Biologic Therapies, Inc. (BTI) is a company with a principal strategy of seeking out and developing innovative, proprietary and patented technologies to meet the needs of the emerging autologous orthobiologic market. BTI’s mission is to provide proprietary, groundbreaking medical technologies that significantly enhance the body’s natural healing ability, providing patients with improved outcomes and quicker restoration of function. The Company’s initial focus and products provide extended access to this market within the well-established orthopedic medical device market. BTI is well positioned to become a leading provider of medical devices and systems for autologous orthobiolgics by advancing the use of stem cell therapy throughout medicine.
Formed as a partnership between Scorpion Medical, Inc. of Florida, a precision manufacturer of medical devices, and Monet Medical, Inc. of Texas, a medical device development company, Biologic Therapies provides contemporary, pioneering technologies that enable surgeons to treat numerous orthopedic and other medical challenges. One such technology is BTI’s unique new Bio-MACTM Bone Marrow Aspiration Catheter needle, provisional patent number 61/445,624, U.S. patent pending.
Biologic Therapies utilizes advanced medical research to open direct paths to technologies for autologous orthobiologic therapy, which refers to using the body’s own stem cells that self-renew, have the ability to change into other types of cells, and accelerate healing. BTI is developing proprietary products and surgical protocols designed to optimize this type of therapy. It is management’s belief that BTI’s state-of-the-art products will propel the Company to emerge as an industry leader, and that by the year 2015, BTI will have implemented a new ‘Standard of Care’ with its products and system technologies.
Autologous orthobiologics is a relatively new medical science that utilizes the body's own stem cells to speed healing within muscle, tendon, ligament, bone and cartilage. This exciting, emerging technology is in its pioneering stage with tremendous growth potential. Its expansion and the number of technologies and treatments for patients both young and old will continue as more is learned and confidence is built through continued research and clinical experience. BTI’s selection of autologous orthobiologic therapy products is based on their utility, profitability and patentability.
Biologic Therapies’ management believes considerable opportunities exist within the high growth niche sector of minimally invasive surgery (MIS). Demographics of an aging population worldwide, increased healthcare demand, and recent sales growth of medical device companies reflects a unique opportunity for creating value within this segment. BTI’s products, systems and procedures are specifically designed to enhance the use of autologous orthobiologic therapy throughout the MIS sector.
Biologic Therapies’ leadership structure is based on extensive industry experience, longstanding relationships with leading physicians and established sales and distribution channels. As BTI continues to research and develop new and simple, yet elegant ways to solve complex medical problems, the Company will quickly become known as a technology innovator. In today’s information age, patients are becoming much more knowledgeable about emerging medical trends and available techniques. Therefore, BTI has embraced the responsibility of providing innovative, contemporary solutions to assist physicians in meeting their patients’ requests, needs and expectations.
Biologic Therapies brings new products to the market based on the needs of the medical community, the needs of patients, and the business requirements of the Company. This strategic methodology ensures that BTI selects appropriate technologies for development and thereby provide the best opportunity for success.
Stem cell therapy has been identified as a major developing segment within the multi-billion dollar autologous orthobiologic market. New breakthroughs and clinical successes in stem cell therapy will help guide Biologic Therapies as it introduces proprietary, innovative products. This strategy ensures the Company’s success of selecting appropriate technologies for development. BTI’s innovative Bio-MACTM Bone Marrow Aspiration Catheter / needle and associated Bio-SPINTM Centrifuge System will fuel the Company’s growth and quickly establish BTI as an industry leader.
For more information on stem cells and stem cell therapies visit the National Institutes of Health web site at http://stemcells.nih.gov/info/basics.
Biologic Therapies’ mission is to provide proprietary, groundbreaking medical technologies that significantly enhance the body's ability to utilize it's own properties to increase healing and provide quicker restoration of function.
Biologic Therapies has a very comprehensive Quality Policy based on ISO 13485 policies and standards, which will help ensure the Company’s success as it grows and introduces more products and services. BTI is committed to continuous quality improvement in all its policies and procedures.